Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

REPORT FROM AAN 2024 – TUESDAY, APRIL 16

April 16, 2024

…s was seen in fatigue scores as evaluated by the novel Patient-Reported Outcomes Measurement Information System Short Form-Fatigue-Multiple Sclerosis 8a (PROMIS-Fatigue-MS-8a) tool. MAb exposure during breastfeeding – safety data Animal studies have detected the secretion of monoclonal antibodies in breast milk and patients are generally advised not to receive MAb therapy during breastfeeding. An analysis of the German MS and Pregnancy Registry id…

REPORT FROM AAN 2024 – MONDAY, APRIL 15

April 15, 2024

…lesion formation in patients who are Black (RR 2.50) and Asian (RR 2.68) (Freeman et al. AAN 2024;P9.006). In addition, sNfL during treatment is predictive of new disease activity, according to a new analysis of ASCLEPIOS I/II (Leist et al. AAN 2024;S42.003). Patients with a high sNfL level at month 3 of treatment had a significant 2.17-fold higher mean annualized rate of new T2 lesions compared to patients with a lower sNfL level (3.67 vs. 1.69)…

Elevated sNfL a possible biomarker of recent seizure in epilepsy

April 5, 2024

…n in NfL was shown in patients with epileptic seizures or febrile seizures compared to healthy controls (Geis et al. Eur J Paediatr Neurol 2023;45:9-13). Overall, mean sNfL levels decreased 3.2% from birth to age 12, then increased 2.7% per year during adolescence. The prognostic value of sNfL has been studied most extensively in status epilepticus (SE). An Italian retrospective study reported higher sNfL levels in SE patients compared to drug-res…

Fluid biomarkers: theory and practice

March 18, 2024

…neurologists would use sNfL testing in routine clinical practice. The most common reasons for testing were to complement clinical/MRI assessments of disease activity (90.7% of respondents), as an additional prognostic factor (82.4%), to classify disease activity (76.8%), for treatment decision-making (73.6%), and to monitor disease activity (72.4%). The preferred timing of sNfL testing was at diagnosis (83.9%), during monitoring of treatment respo…

New consensus statement on MRI biomarkers in MS

February 20, 2024

…g whether to include PRLs in its diagnostic criteria (see McDonald criteria 2024: what changes can we expect?, NeuroSens, January 30, 2024). The NAIMS group stated that additional studies are needed to determine the impact of disease-modifying therapies on PRLs and whether the prevention/resolution of PRLs will improve outcomes. At present, only a few studies have incorporated these imaging biomarkers as an endpoint. A phase II trial of tolebrutin…